How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics

May 26, 2016, 08:50 ET from Chelmsford Park SA

NEW YORK, May 26, 2016 /PRNewswire/ --

Despite the volatility that continues to envelop the Biotech industry, investors see value in this space. Today's pre-market research on directs the investor community's focus on the following Healthcare equities: Radius Health Inc. (NASDAQ: RDUS), Cerus Corp. (NASDAQ: CERS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at:

On Wednesday, shares in Massachusetts headquartered biopharma Company, Radius Health Inc., ended the session at $34.90, which was a correction of 2.13%. The stock recorded a trading volume of 458,092 shares. The Company's shares have advanced 12.87% in the previous three months. The stock is trading 2.75% above its 50-day moving average. Moreover, shares of Radius Health have a Relative Strength Index (RSI) of 55.05. Sign up and read the alert on RDUS at:

Biomedical products Company, Cerus Corp.'s stock gained 1.81%, to close the day at $5.63 with a total volume of 978,737 shares traded. The Company's shares have advanced 13.05% in the previous three months. The stock is trading 2.87% above its 200-day moving average. Additionally, shares of Cerus have an RSI of 49.32. The complimentary trade alert on CERS can be turned on at:

Shares in Arrowhead Pharmaceuticals Inc., a biopharma Company, which develops novel drugs to treat intractable diseases in the U.S., recorded a trading volume of 394,709 shares at the close of the last trading session and ended the day 2.26% higher at $5.88. The stock has advanced 52.33% in the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 9.54% and 10.99%, respectively. Furthermore, Arrowhead Pharmaceuticals' stock has an RSI of 60.55. Register for free on and access key information on ARWR at:

California headquartered clinical-stage biotech Company, Five Prime Therapeutics Inc.'s stock finished Wednesday's session at $43.73, which was a correction of 1.38%. A total volume of 378,348 shares was traded. The Company's shares have advanced 33.94% in the previous three months and 5.37% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 2.70% and 31.67%, respectively. Furthermore, shares of Five Prime Therapeutics have an RSI of 52.89.  FPRX alerts are available for free at:


Active Wall Street: 

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

AWS has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly at: Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom Email: Phone number:  1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA